| Date | Time | Source | |
| 03/19/2010 | 5:07PM | DJN | UPDATE: Teva Sees $9.2 Billion Europe Revenue By 2015 Without Deals
Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) can reach its goal of $9.2 billion in European revenue for 2015 without making additional deals, following Thursday's agreement to buy Germany's Ratiopharm Group International for about $5 billion. The Israeli generic drug giant emerged Thursday as the winner of an auction... More...>> |
| 03/19/2010 | 12:55PM | DJN | MARKET SNAPSHOT: U.S. Stocks Fall As India Hike, Oil Strikes Nerve
By Donna Kardos Yesalavich U.S. stocks fell broadly Friday, taking a breather from their recent winning streak as declines in commodities drove the energy sector lower, and as worries over the impact of global-rate hikes resurfaced. The Dow Jones Industrial Average (DJI) was down 51 points, or 0.5%, at 10,728 in recent... More...>> |
| 03/19/2010 | 11:34AM | DJN | MARKET SNAPSHOT: U.S. Stocks Turn Lower On Greece, Financials
By Donna Kardos Yesalavich U.S. stocks fell in choppy trading on Friday as resurrected concerns over financial aid for Greece perturbed investors, driving up the dollar. The Dow Jones Industrial Average (DJI) was down 38 points, or 0.4%, to 10,741. 3M (MMM) was the measure's worst performer, down 1.5%. Pfizer (PFE) also... More...>> |
| 03/19/2010 | 9:38AM | MWUS | Wall Street News Alert: Breaking News: UYMG - March 19, 2010
Wall Street News Alert's "stocks to watch" this morning are: Unity Management Group Inc. (PINKSHEETS: UYMG), Boston Scientific Corporation (NYSE: BSX), UnitedHealth Group (NYSE: UNH) and Pfizer Inc. (NYSE: PFE). Yesterday after the markets closed, Unity Management Group Inc. (PINKSHEETS: UYMG) issued a press release announcing... More...>> |
| 03/19/2010 | 8:11AM | DJN | EU Panel Backs Marketing Authorization For Nivestim
The Committee for Medicinal Products for Human Use, or CHMP, said Friday it is backing the granting of a marketing authorization for Nivestim (filgrastim), from Hospira U.K. Ltd., intended for the treatment of neutropenia. MAIN FACTS: -The Committee also adopted positive opinions recommending the granting of marketing... More...>> |
| 03/17/2010 | 6:53PM | DJN | Roche CEO Touts Pipeline, Remains Open To More Deals
Roche Holding AG (RHHBY, ROG.VX) Chief Executive Severin Schwan said the integration of its $46.8 billion takeover of Genentech Inc. is "by and large completed," expressed his confidence in the Swiss drug giant's pipeline, and said he remains open to yet more deal-making. His comments came in an interview the day before... More...>> |
| 03/17/2010 | 3:41PM | DJN | EPA To Require Beefed Up Labels For Pet Flea, Tick Products
The Environmental Protection Agency is requiring beefed up labeling for flea and tick products used on dogs and cats amid an increasing number of reports showing that pets given the pesticides may suffer from seizures and die. The EPA wants companies to make instructions on the products' labels more clear so people don't... More...>> |
| 03/17/2010 | 9:04AM | DJN | UPDATE: Cyprotex '09 Profit Falls As Drugmakers Cut Spending
Drug research services company Cyprotex PLC (CRX.LN) Wednesday reported a 15% decline in full-year pretax profit after pharmaceutical companies cut back spending on research and development. But Chief Executive Anthony Baxter told Dow Jones Newswires the opportunities for Cyprotex to sign up big strategic customers--those... More...>> |
| 03/17/2010 | 8:00AM | BW | Study Shows Prevenar 13* Is Immunogenic In Young Children Previously Vaccinated With Prevenar*
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal... More...>> |
| 03/16/2010 | 6:49PM | DJN | UPDATE:Sen Kohl Probes Price Differences In Drugs In US, Abroad
Sen. Herb Kohl (D., Wisc.) is pressing pharmaceutical companies such as GlaxoSmithKline PLC (GSK, GSK.LN), Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE) to explain why their drugs often cost four times more in the U.S. than in other countries. Letters from the Special Committee on Aging, which Kohl chairs, ask the chief... More...>> |
| 03/16/2010 | 5:52PM | DJN | Sen Kohl Probes Price Differences In Drugs Sold In US, Abroad
Sen. Herb Kohl (D., Wisc.) is pressing pharmaceutical companies such as GlaxoSmithKline PLC (GSK, GSK.LN), Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE) to explain why their drugs often cost four times more in the U.S. than in other countries. Letters from the Special Committee on Aging, which Kohl chairs, ask the chief... More...>> |
| 03/16/2010 | 1:11PM | DJN | Emerging Markets To Make Half Of Pharma Sales Growth By '13 -Study
About half the pharmaceutical industry's growth is expected to come from emerging markets by 2013, with China taking the place of France as the world's third-largest market by as soon as next year, according to a new study released Tuesday. The report published by IMS Health Inc. (RX), a third-party data collector for... More...>> |
| 03/15/2010 | 6:54PM | DJN | Bigger Lipitor Dose Better For Some High-Risk Patients -Study
DOW JONES NEWSWIRES A study found that a bigger dose of Pfizer Inc.'s (PFE) Lipitor was about a third better at cutting the incidence of major cardiovascular events in certain high-risk patients. The results of the Treating to New Targets study, originally funded by Pfizer and comparing doses of 80 and 10 milligrams, could... More...>> |
| 03/15/2010 | 3:36PM | DJN | 2nd UPDATE: Bausch & Lomb Taps Ex-Schering Executives In Rebuild
Bausch & Lomb Inc. tapped a pair of former Schering-Plough executives, including naming noted drugmaker turnaround artist Fred Hassan as its new chairman, as it continues its multi-year rebuilding efforts. Hassan will run the contact lens and eye-care products maker along with another former Schering-Plough executive... More...>> |
| 03/15/2010 | 3:30PM | BW | Intensive Lipitor Therapy Was Associated With Reduced Risk Of Cardiovascular Events In Two High-Risk Patient Groups
Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating... More...>> |
| 03/15/2010 | 2:24PM | DJN | UPDATE:Bausch & Lomb Taps Ex-Schering-Plough Executives In Turnaround
Bausch & Lomb Inc. (BOL) named former Schering-Plough (SGP)chairman and chief executive--and noted drug maker turnaround artist--Fred Hassan as its new chairman as the maker of contact lenses and eye-care products continues its multi-year restructuring efforts. Hassan will run the company along with another former... More...>> |
| 03/15/2010 | 7:23AM | DJN | UK Body Backs Enbrel, Humira In Psoriatic Arthritis Treatment
The U.K.'s healthcare cost-effectiveness watchdog Monday recommended Pfizer Inc.'s (PFE) arthritis drug Enbrel and Abbott Laboratories' (ABT) Humira as first choices for treating adults with active and progressive psoriatic arthritis. The U.K.'s National Institute for Health and Clinical Excellence, or NICE, said arthritis... More...>> |
| 03/12/2010 | 4:49PM | DJN | MARKET SNAPSHOT: Stocks End Mixed As Financials Snap Win Streak
By Peter McKay Major U.S. stock indexes finished mixed on Friday as investors paused their recent betting spree in the financial sector, which snapped a 10-day winning streak. The Dow Jones Industrial Average (DJI) rose for a fourth straight day, ending 12.85 points higher, up 0.1%, at 10,624.69, led by a 3.4% gain in... More...>> |
| 03/12/2010 | 4:03PM | DJN | MARKET SNAPSHOT: Stocks Rangebound As Financials Pull Back
By Peter McKay The recent momentum in financial stocks ebbed, leaving the market at risk of snapping a three-day winning streak as Friday's closing bell neared. Investors digested mixed readings of consumer spending and sentiment, and many traders avoided big bets ahead of a packed calendar of economic releases next week... More...>> |
| 03/12/2010 | 2:51PM | DJN | MARKET SNAPSHOT: Stocks Rangebound As Financials Pull Back
By Peter McKay U.S. financial stocks' recent momentum ebbed Friday, leaving the market in a narrow range as investors digested mixed readings of consumer spending and sentiment. Traders generally avoided big bets ahead of an even more packed economic calendar next week. But a few key corporate announcements managed to... More...>> |